The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Dulić, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J. W., Elledge, S. J., & Reed, S. I. (1994) · Cell · doi:10.1016/0092-8674(94)90379-4 · Cited by 1,465
How Proteolysis Drives the Cell Cycle
King, R. W., Deshaies, R. J., Peters, J.-M., & Kirschner, M. W. (1996) · Science · doi:10.1126/science.274.5293.1652 · Cited by 1,273
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P. G., Niesvizky, R., Alexanian, R., Limentani, S. A., Alsina, M., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05188.x · Cited by 740
Richardson, P. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D. S., Irwin, D., Schuster, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7779 · Cited by 649
Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J. E., Hagemeister, F., Fayad, L., Dang, N. H., Samaniego, F., Wang, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.108 · Cited by 526
The proteasome as a target for cancer therapy.
Voorhees, P. M., Dees, E. C., O’Neil, B. H., & Orlowski, R. Z. (2003) · PubMed · Cited by 455
The role of the ubiquitin-proteasome pathway in apoptosis
Orlowski, R. Z. (1999) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400505 · Cited by 386
Pei, X.-Y., Dai, Y., & Grant, S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0561 · Cited by 382
Read, M. A., Neish, A. S., Luscinskas, F. W., Palombella, V. J., Maniatis, T., & Collins, T. (1995) · Immunity · doi:10.1016/1074-7613(95)90030-6 · Cited by 347
Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells
Qin, J.-Z., Ziffra, J., Stennett, L., Bodner, B., Bonish, B. K., Chaturvedi, V., Bennett, F., Pollock, P. M., Trent, J. M., Hendrix, M. J. C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0676 · Cited by 336
Orlowski, R. Z., Voorhees, P. M., Garcia, R. A., Hall, M. D., Kudrik, F. J., Allred, T., Johri, A. R., Jones, P. E., Ivanova, A., Van Deventer, H. W., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2911 · Cited by 319
Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat
Cavaletti, G., Tredici, G., Petruccioli, M. G., Dondè, E., Tredici, P., Marmiroli, P., Minoia, C., Ronchi, A., Bayssas, M., & Griffon Etienne, G. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00300-8 · Cited by 281
Self-citationYu, C., Rahmani, M., Conrad, D., Subler, M., Dent, P., & Grant, S. (2003) · Blood · doi:10.1182/blood-2003-03-0737 · Cited by 259
Landowski, T. H., Megli, C. J., Nullmeyer, K. D., Lynch, R. M., & Dorr, R. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3684 · Cited by 202
Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma
Kondagunta, G. V., Drucker, B., Schwartz, L., Bacik, J., Marion, S., Russo, P., Mazumdar, M., & Motzer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.155 · Cited by 192
Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine.
Pisano, C., Pratesi, G., Laccabue, D., Zunino, F., Giudice, P. L., Bellucci, A., Pacifici, L., Camerini, B., Vesci, L., Castorina, M., et al. (2003) · PubMed · Cited by 181
Self-citationCavaletti, G., Cavalletti, E., Oggioni, N., Sottani, C., Minoia, C., D’Incalci, M., Zucchetti, M., Marmiroli, P., & Tredici, G. (2000) · PubMed · Cited by 167
Self-citationCavaletti, G., Tredici, G., Marmiroli, P., Petruccioli, M. G., Barajon, I., & Fabbrica, D. (1992) · Acta Neuropathologica · doi:10.1007/bf00227662 · Cited by 164
Self-citationCavaletti, G., Cavalletti, E., Oggioni, N., Sottani, C., Minoia, C., D’Incalci, M., Zucchetti, M., Marmiroli, P., & Tredici, G. (2001) · Journal of the Peripheral Nervous System · doi:10.1046/j.1529-8027.2001.01008-5.x · Cited by 157
Self-citationShah, M. H., Young, D., Kindler, H. L., Webb, I. J., Kleiber, B., Wright, J., & Grever, M. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0422 · Cited by 139
Persohn, E., Canta, A., Schoepfer, S., Traebert, M., Mueller, L., Gilardini, A., Galbiati, S., Nicolini, G., Scuteri, A., Lanzani, F., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.006 · Cited by 132
Self-citationRegulation of transcription factors by protein degradation
Desterro, J. M. P., Rodríguez, M. S., & Hay, R. T. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000760 · Cited by 128
Cavaletti, G., Cavalletti, E., Montaguti, P., Oggioni, N., Negri, O. D., & Tredici, G. (1997) · PubMed · Cited by 124
Self-citationA Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma
Miguel, J. F. S., Bladé, J., Boccadoro, M., Cavenagh, J. D., Glasmacher, A., Jagannath, S., Lonial, S., Orlowski, R. Z., Sonneveld, P., & Ludwig, H. (2006) · The Oncologist · doi:10.1634/theoncologist.11-1-51 · Cited by 120
Effect of Recombinant Human Nerve Growth Factor on Cisplatin Neurotoxicity in Rats
Tredici, G., Braga, M., Nicolini, G., Miloso, M., Marmiroli, P., Schenone, A. E., Nobbio, L., Frattola, L., & Cavaletti, G. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7174 · Cited by 68
Self-citationCavaletti, G., Oggioni, N., Sala, F., Pezzoni, G., Cavalletti, E., Marmiroli, P., Petruccioli, M. G., Frattola, L., & Tredici, G. (2000) · Toxicology Letters · doi:10.1016/s0378-4274(00)00269-1 · Cited by 64
Self-citationBortezomib and its role in the management of patients with multiple myeloma
Orlowski, R. Z. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.2.171 · Cited by 35
rhGGF2 protects against cisplatin-induced neuropathy in the rat
ter Laak, M. P., Hamers, F. P. T., Kirk, C. J., & Gispen, W. H. (2000) · Journal of Neuroscience Research · Cited by 34
Bortezomib for Myeloma — Much Ado about Something
Dispenzieri, A. A. (2005) · New England Journal of Medicine · doi:10.1056/nejme058059 · Cited by 27
Musto, P., Falcone, A. P., Sanpaolo, G., Guglielmelli, T., Zambello, R., Balleari, E., Catalano, L., Spriano, M., Cavallo, F., Sala, A. L., et al. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.06.027 · Cited by 17
Cited by
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Self-citationNilius, B., & Szallasi, A. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008268 · Cited by 506
Proteasome inhibitors in multiple myeloma: 10 years later
Moreau, P., Richardson, P. G., Cavo, M., Orlowski, R. Z., San Miguel, J. F., Palumbo, A., & Harousseau, J.-L. (2012) · Blood · doi:10.1182/blood-2012-04-403733 · Cited by 490
Argyriou, A. A., Iconomou, G., & Kalofonos, H. P. (2008) · Blood · doi:10.1182/blood-2008-04-149385 · Cited by 432
Metadata
- Authors
- Cavaletti, G., Gilardini, A., Canta, A., Rigamonti, L., Rodriguez-Menendez, V., Ceresa, C., Marmiroli, P., Bossi, M., Oggioni, N., D'Incalci, M., & De Coster, R.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2007-03
- Volume
- 204
- Issue
- 1
- Pages
- 317-325
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W2039923434
- Cited by
- 265
- References
- 32
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.